162 related articles for article (PubMed ID: 2441082)
1. Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis.
Susawa T; Yui Y; Hattori R; Takahashi M; Aoyama T; Takatsu Y; Sakaguchi K; Yui N; Kawai C
Jpn Circ J; 1987 Apr; 51(4):431-5. PubMed ID: 2441082
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.
Susawa T; Yui Y; Hattori R; Takatsu Y; Yui N; Takahashi M; Aoyama T; Murohara Y; Shirotani M; Kawai C
Jpn Circ J; 1988 Jan; 52(1):72-8. PubMed ID: 3129601
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
[TBL] [Abstract][Full Text] [Related]
4. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR
Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691
[TBL] [Abstract][Full Text] [Related]
5. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
6. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
Yasuda T; Gold HK; Fallon JT; Leinbach RC; Garabedian HD; Guerrero JL; Collen D
J Am Coll Cardiol; 1989 May; 13(6):1409-14. PubMed ID: 2495318
[TBL] [Abstract][Full Text] [Related]
7. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
[TBL] [Abstract][Full Text] [Related]
8. The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
Tomaru T; Uchida Y; Sonoki H; Tsukamoto M; Sugimoto T
Angiology; 1989 May; 40(5):429-35. PubMed ID: 2495745
[TBL] [Abstract][Full Text] [Related]
9. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
Martin U; Fischer S; Sponer G
J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
[TBL] [Abstract][Full Text] [Related]
10. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
Uriuda Y; Wang QD; Hatori N; Nordlander R; Sjöquist PO; Mattsson C; Rydén L
J Pharmacol Toxicol Methods; 1998 Mar; 39(2):81-9. PubMed ID: 9694166
[TBL] [Abstract][Full Text] [Related]
11. Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
Gu S; Ducas J; Patton JN; Greenberg D; Prewitt RM
Chest; 1992 Jun; 101(6):1684-90. PubMed ID: 1600792
[TBL] [Abstract][Full Text] [Related]
12. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.
Topol EJ; Califf RM; George BS; Kereiakes DJ; Rothbaum D; Candela RJ; Abbotsmith CW; Pinkerton CA; Stump DC; Collen D
Circulation; 1988 May; 77(5):1100-7. PubMed ID: 2966017
[TBL] [Abstract][Full Text] [Related]
13. Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis.
Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
Jpn J Pharmacol; 1993 Nov; 63(3):319-25. PubMed ID: 8107325
[TBL] [Abstract][Full Text] [Related]
14. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
Van de Werf F; Jang IK; Collen D
J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
[TBL] [Abstract][Full Text] [Related]
15. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Yui Y; Kawai C
J Cardiovasc Pharmacol; 1993 Dec; 22(6):834-40. PubMed ID: 7509901
[TBL] [Abstract][Full Text] [Related]
16. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
Shebuski RJ; Stabilito IJ; Sitko GR; Polokoff MH
Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
[TBL] [Abstract][Full Text] [Related]
17. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
[TBL] [Abstract][Full Text] [Related]
18. A novel modified tissue-type plasminogen activator (t-PA), E6010, reduces reperfusion arrhythmias induced after coronary thrombolysis--comparison of native t-PA and urokinase.
Saito M; Suzuki S; Yui Y; Kawai C
Jpn Circ J; 1995 Aug; 59(8):556-64. PubMed ID: 7474300
[TBL] [Abstract][Full Text] [Related]
19. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
[TBL] [Abstract][Full Text] [Related]
20. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
Nicolini FA; Mehta JL; Nichols WW; Saldeen TG; Grant M
Circulation; 1990 Mar; 81(3):1115-22. PubMed ID: 1689620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
